Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

DOI PDF 1 Citations
  • Giovanni Barosi
    Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy;
  • Ruben Mesa
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ;
  • Guido Finazzi
    Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
  • Claire Harrison
    Department of Haematology, St Thomas Hospital, London, United Kingdom;
  • Jean-Jacques Kiladjian
    Saint-Louis Hospital and Paris Diderot University, Paris, France;
  • Eva Lengfelder
    Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany;
  • Mary F. McMullin
    Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom;
  • Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy;
  • Alessandro M. Vannucchi
    University of Florence, Florence, Italy;
  • Carlos Besses
    Department of Hematology, Institut Hospital del Mar d'Investigations Mediques, Barcelona, Spain;
  • Heinz Gisslinger
    University of Vienna, Department of Internal Medicine, Wien, Austria;
  • Jan Samuelsson
    Department of Internal Medicine, Karolinska Institute at Stockholm South Hospital, Stockholm, Sweden;
  • Srdan Verstovsek
    MD Anderson Cancer Center, Houston, TX;
  • Ronald Hoffman
    Division of Hematology/Oncology, Pathology and Surgery, Tisch Cancer Institute, Myeloproliferative Disorders Research Consortium, Mount Sinai School of Medicine, New York, NY;
  • Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; and
  • Francisco Cervantes
    University of Barcelona, Hospital Clínic, Hematology Department, Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
  • Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; and
  • Tiziano Barbui
    Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy;

Abstract

<jats:title>Key Points</jats:title><jats:p>Evidence exists that ELN criteria for response in ET and PV issued in 2009 do not provide relevant measures of benefit for patients. Revised recommendations for assessing response are provided.</jats:p>

Journal

  • Blood

    Blood 121 (23), 4778-4781, 2013-06-06

    American Society of Hematology

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top